Lilly and Novo intensify the weight loss and diabetes market battle with new efficacy, oral drug, and cardiovascular data.
Akums gets DCGI approval for 0.5 mg Colchicine tablets, marking a first-time-in-India milestone in preventive cardiology and cardiovascular care.
Apixaban oral suspension is Lupin's latest formulation development, receiving tentative US FDA approval for its 1.25 mg/mL product as an alternative to tablets.
Andhra Pradesh cancer cases are projected to reach 64,990 among adults in 2026, highlighting gaps in screening alongside expanding cancer-care infrastructure.
Flu surveillance flags H1N1 as India’s dominant strain this September, with WHO data showing a 75 percent share of positive samples.
Oral obesity drugs are gaining momentum as Novo Nordisk's USD 2.6 billion deal with Hengrui highlights the shift toward next-generation treatments.
AIIMS Delhi secures approval for a major critical care capacity boost, adding a dedicated infectious diseases block and multi-level parking at JPN Apex Trauma Center.
Pharma majors bet big on next-gen cancer therapies as Merck and AstraZeneca invest billions in innovative oncology assets.
Roche is advancing autonomous AI labs by combining artificial intelligence, robotics and laboratory automation to transform pharmaceutical drug R&D.
The Pharma Manufacturing & Automation Excellence Awards 2026(PM&AE Awards 2026) celebrates the organizations, leaders, and professionals who are redefining pharmaceutical manufacturing through operational excellence, smart manufacturing
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
